Gilead Terminates License Agreement for Long-Acting Injectable HIV Investigational ProductPRNewsWire • 06/26/20
DURECT Corporation: DUR-928 May Benefit COVID-19 Patients With Acute Organ InjurySeeking Alpha • 05/13/20
DURECT Corp (DRRX) CEO James Brown on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Durect (DRRX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 04/28/20
DURECT Corporation (DRRX) CEO Jim Brown on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/04/20
Eli Lilly's Acquisition Strategy, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha • 01/22/20
Biopharma Durect says FDA committee ended meeting with split vote on post-surgical pain treatmentMarket Watch • 01/17/20
Biopharma Durect shares halted ahead of FDA committee meeting on post-surgical pain treatmentMarket Watch • 01/16/20
DURECT Corp (DRRX) CEO James Brown on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
DURECT Corporation: DUR-928 Data In Severe Alcoholic Hepatitis To Be Showcased At Upcoming AASLD MeetingSeeking Alpha • 10/24/19
DURECT Corporation (DRRX) CEO Jim Brown on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/02/19
Durect's Latest Progress Between Liver Disease Drug And Partnership Launches It ForwardSeeking Alpha • 08/01/19
DURECT Corp (DRRX) CEO James Brown on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/09/19